Molten Ventures VCT annual results show steady NAV, positive total return, ongoing dividends and buybacks, but lower cash and reduced tax relief.
This article covers information on Molten Ventures VCT PLC.
LON:MVCTLast updated:
Molten Ventures VCT has delivered a fairly solid set of annual results for the year ended 31 March 2026. This is not a blow-the-doors-off update, but it is a respectable one. The big picture is that portfolio valuations were broadly stable, total return nudged back into positive territory, and the company kept paying a healthy tax-free dividend while continuing its buyback policy.
For retail investors, that matters because VCTs live and die by three things – net asset value, cash discipline, and the quality of the underlying portfolio. On those measures, Molten looks steady rather than spectacular, which is probably a decent outcome in a still-choppy market for early-stage technology investing.
| Metric | 2026 | 2025 |
|---|---|---|
| Net assets | £114.4 million | £118.2 million |
| NAV per share | 41.3p | 43.0p |
| NAV total return | +1.2% | -5.6% |
| Share price | 37.8p | 37.5p |
| Cash and cash equivalents | £23.0 million | £32.2 million |
| Total dividend for the year | 2.10p | 2.15p |
| Gain/(loss) after tax | £1.2 million | (£7.5 million) |
| Exits realised | £5.5 million | Not disclosed here |
| New and follow-on investments | £6.5 million | £11.2 million |
The headline NAV per share fell from 43.0p to 41.3p, a drop of 4.0%. On its own, that is mildly disappointing. But VCTs are designed to pay out regular dividends, so the better measure is total return, which adds dividends back in.
On that basis, Molten’s total return per share edged up from 160.6p to 161.1p, and NAV total return was positive 1.2% for the year. That is a meaningful improvement on the prior year’s negative 5.6% and suggests the portfolio has stopped sliding and started to stabilise.
My read is simple: this is a recovery year, not a breakout year. Investors looking for proof that the worst of the tech valuation reset may be over will find some comfort here.
The portfolio is increasingly concentrated in technology, which is exactly what you would expect from Molten. Enterprise technology is now the biggest slice at £40.0 million, or 35.0% of NAV, followed by deeptech and hardware at £26.5 million, or 23.2%.
Cash and other assets fell to £23.0 million from £32.2 million, now representing 20.1% of NAV versus 27.2% a year ago. That lower cash weighting is not automatically bad – it partly reflects investment activity, dividends and buybacks – but it does mean there is a bit less balance sheet cushioning than before.
The manager says 66% of the portfolio by value, excluding cash, is performing broadly as expected. Another 10% is either new or still early in its commercial journey, while 24% needs more help to reach a viable growth path or exit. That is actually quite a useful bit of honesty, and it tells you this remains a venture portfolio with real risk, not a smooth compounding machine.
Riverlane was the clear standout, with a valuation uplift of £5.8 million year on year. The VCT also highlighted Thought Machine and Form3 as well-funded category contenders, and together with Riverlane those three holdings make up £26.5 million, or 23% of NAV.
On the other side, Focal Point Positioning was marked down by £1.7 million because it is still in extended commercial negotiations and has not yet closed a deal beyond proof of concept. Oliva Health was written down by £1.0 million and Melio Healthcare, trading as IMU Bioscience, by £0.6 million.
That mix matters. One strong winner can offset several laggards in venture capital, but it also shows how dependent returns can be on a handful of larger holdings coming good.
Molten completed four exits during the year, generating £5.5 million of proceeds and realised gains of £0.3 million overall. That is positive, but only just. It says the manager is getting deals done, though not at blockbuster prices.
On the investment side, the VCT put £6.5 million into four new and three follow-on investments. New names included Duel Holdings, Polymodels Hub, General Index and Maia Technology. Follow-ons went into IMU Bioscience, Oliva Health and Focal Point Positioning.
That pace of deployment was lower than the previous year’s £11.2 million. In the current market, I’d call that sensible rather than timid. If valuations are still uneven, discipline beats activity for activity’s sake.
Income investors will focus on the dividend, and this remains one of the more attractive features of the story. The total dividend for the year is 2.10p per share, made up of a 1.00p interim dividend and a proposed final dividend of 1.10p payable on 30 September 2026, subject to shareholder approval.
That is slightly lower than last year’s 2.15p, so there has been a small trim. Still, the company says this is equivalent to a tax-free dividend yield of 5.1% of NAV, which remains appealing.
Buybacks were also strong. The company repurchased 14,831,325 shares during the year at an average price of 39.4p, and 100% of shares offered for repurchase were bought back. For VCT investors, that liquidity support is a genuine plus because selling VCT shares can otherwise be awkward.
After the year end, Molten raised £16.4 million before costs under its 2025/26 offer for subscription. That fresh cash gives the VCT more firepower and reduces the immediate pressure created by the fall in year-end cash balances.
There are two obvious watchpoints. First, cash and cash equivalents dropped by 28.6% to £23.0 million. The VCT still has ample liquidity today, but that cushion is smaller than it was.
Second, the tax backdrop has worsened. The Government reduced upfront income tax relief on new VCT investments from 30% to 20% from 6 April 2026. Both the chairman and manager are clearly unhappy about that, and with good reason – lower tax relief could make fundraising harder across the sector.
There is also a technical point on reserves worth noting. Total distributable reserves were £68.3 million, but £52.9 million of that is restricted and only becomes unrestricted between 1 April 2027 and 1 April 2029. In plain English, the reserves exist, but not all of them are freely available for near-term distributions. Future dividends are likely to depend heavily on cash flow.
This update reads like a steadying of the ship. NAV per share slipped, but total return turned positive again. The portfolio still has some exciting names, Riverlane provided a meaningful uplift, and the company continues to support shareholders with dividends and buybacks.
The negatives are real too. Cash is lower, some holdings were marked down, and the reduction in VCT tax relief could make the whole sector less attractive to new money. So this is not a risk-free income vehicle dressed up as a tech fund – it is still a venture capital trust, with all the bumps that come with that.
Overall, I’d call these results cautiously positive. Molten Ventures VCT is showing resilience, portfolio discipline and enough underlying progress to keep investors interested. The next big test is whether that stable valuation backdrop can turn into stronger exits and more consistent NAV growth over the next 12 months.
Related
Polar Capital Technology Trust sees 102% NAV growth in FY2026, beating its benchmark by 47 points thanks to AI and semiconductor exposure.
JoshuaJuly 10, 2026
Impax Q3 AUM rises to £23.3bn despite £1.7bn net outflows, driven by market gains and strong investment performance.
JoshuaJuly 10, 2026
MJ Gleeson FY2026 trading update: steady profits, mixed home sales with operational restructuring improving outlook.
JoshuaJuly 10, 2026
Last updated
Category
InvestingViews
5 viewsLikes
No ratings yet
No comments yet - start the conversation.